Clinical Research

GISSI-2 Int´l

• The tPA/SK mortality trial
• SK vs. tPA, SC heparin vs no heparin
• 723 patients included 
• The Lancet 1990; 336: 71-75
• Argentina

 

ECLA2 / RAPT

• Ridogrel Aspirin Patency Trial
• Ridogrel vs Aspirin
• 907 patients included 
• Circ. Vo 89, No.2 February 1994:588
• Argentina-Brazil-Uruguay

 

ECLA 3

• Clinical Predictors of In-Hospital Prognosis in Unstable Angina: ECLA 3
• Epidemiology
• 1130 patients included 
• Am.Heart J 137 (2) 322-331, 1999
• Argentina

 

ISIS-4

• The 4th international study of infarct survival
• Captopril vs. placebo: magnesium vs. placebo; oral nitrates vs. placebo
• 3572 patients included 
• The Lancet, March 18, 1995; 345:669
• Argentina -Brazil-Chile-Colombia-México-Uruguay-Venezuela

 

HOPE

• Heart Outcome Prevention Evaluation
• Ramipril / Vitamin E
• 1344 patients included 
• NEJM Vol 342 No.3, January 20, 2000. The Lancet Vol 355- Jan. 22, 2000 (DIABETES)
• Argentina

 

CORE

• Collaborative Organization for Rheothrex Evaluation
• Rheothrex
• 410 patients included 
• Circulation Vol 96 No. 1- 1, July 1997:192
• Argentina

 

GIK PILOT

• Glucose-Insulin-Potassium Pilot Trial
• Glucose / insulin / potassium
• 407 patients included 
• Circulation 98:227- Nov 24, 1998
• Argentina-Brazil-Chile-México-Uruguay-Venezuela

 

COBALT

• Continuous Infusion vs. Double-bolus administration of Alteplase
• Alteplase
• 419 patients included 
• NEJM Vol.337 No. 16, 1124-1130 Oct. 16, 1997
• Argentina

 

ATLAS

• Adjuvant Tamoxifen Longer Against Shorter
• Tamoxifen
• 893 patients included 
• Lancet. 2013 Mar 9;381(9869):805-16
• Argentina

 

PARAGON A

• Lamifiban, heparin or both in UA
• GPIIb / IIIa Platelet Receptor blocker vs. heparin
• 103 patients included 
• Circulation 1998; 97: 2386-2395
• Argentina

 

PURSUIT

• Inhibition of Platalet Glycoprotein IIb / IIIa with Eptifibatide in patients with ACS
• Integrelin vs. placebo
• 140 patients included 
• NEJM 1998; 339 (7): 436
• Argentina

 

ASSENT 1

• Safety assessment of single bolus administration of TNK in AMI
• TNK -tPA
• 113 patients included 
• American Heart Journal Vol 137 No. 5, May 1999
• Argentina

 

OASIS-II

• Organization to Assess Strategies for Ischemic Syndromes
• Hirudin/heparin
• 660 patients included 
• The Lancet Vol 353 No. 9151; 6 Feb. 1999
• Argentina

 

PARAGON B

• IIb / IIIa antagonists during ACS
• Lamifiban vs. heparin
• 300 patients included 
• Am Heart J. 2000; 139 (4): 563
• Argentina

 

SYMPHONY

• Comparison of Sibrafiban with aspirin for prevention of cardiovascular events after ACS
• Sibrafiban
• 235 patients included 
• The Lancet Vol 355 No. 9201 Pag. 337-345 Saturday 29 January 2000.
• Argentina

 

2nd SYMPHONY

• Secondary prevention after acute coronary syndromes
• Aspirin / Sibrafiban
• Circulation 2001; 103: 1727-1733

 

ASSENT 2

• Assessment of the Safety and Efficacy of a New Thrombolytic
• TNK-tPA vs rtPA
• 600 patients included 
• The Lancet, Vol 354- 716-22, August 28, 1999
• Argentina

 

CREATE-ECLA (GIK2)

• Glucose insulin potassium infusion vs conventional treatment in patients receiving reperfusion therapy for the treatment of acute myocardial infarction
• Glucose / insulin / potassium
• 3804 patients included 
• JAMA January 26, 2005. Vol 293 Nª 4 Page 437
• Argentina, Kuwait, Venezuela, Brazil, Italy, Greece, Chile, India, Dominican Rep., New Zealand, Spain, Colombia, México, USA, United Arab Emirates, Belgium, Paraguay, Panama, South Africa

 

CURE

• Clopidogrel in UA to prevent recurrent events
• Clopidogrel
• 512 patients included 
• NEJMed 2001; 345: 494-502 The Lancet 2001; 358: 527-533
• Argentina

 

HERO-2

• Hirulog early reperfusion / occlusion
• Hirulog vs Heparin
• 1626 patients included 
• The Lancet 2001, 358:1855-1863
• Argentina-Chile-México-Panamá-Paraguay-Puerto Rico- Rep. Dominicana -Venezuela

 

VALIANT

• VALsartan In Acute myocardial iNfarcTion
• Valsartan vs captopril
• 635 patients included
• N Engl J Med 2003; 349:1893-1906, Nov 13, 2003.
• Argentina

 

ASSENT 3

• ASsessment of the Safety and Efficacy of New Thrombolytic regimens
• TNK-tPA
• 217 patients included
• The Lancet, 358: 605-613
• Argentina

 

PACT

• Primary Angioplasty with a strategy of Short Acting Thrombolysis Vs Immediate Planned rescue Angioplasty in AMI
• rt-PA
• 28 patients included
• JACC Vol 34 No.7, 1954-1962, Dec 1999
• Argentina

 

INTER-HEART

• A Global Study of risk Factors for Acute Myocardial Infarction
• 330 patients included
• The Lancet-Vol 364- 937-952, Sept. 11, 2004
• Argentina

 

ONTARGET

• Ongoing Telmisartan alone and in combination with Ramipril global endpoint trial
• Telmisartan / Ramipril
• 1194 patients included
• N Engl J Med 2008; 358:1547-1559, April 10, 2008
• Argentina

 

TRANSCEND

• Ongoing Telmisartan alone and in combination with Ramipril global endpoint trial
• Telmisartan
• 468 patients included
• Lancet. 2008 Sep 27;372(9644):1174-83. Epub 2008 Aug 29
• Argentina

 

DREAM

• Diabetes Reduction Assessment with Ramipril and rosiglitazone Medication
• Ramipril and Rosiglitazone
• 879 patients included
• Diabetes Care. 2008 May;31(5):1007-14. Epub 2008 Feb 11
• Argentina

 

DREAM ON

• Passive follow up of the Dream Trial patients
• No drugs tested
• 554 patients included
• Argentina

 

UPLIFT

• Assessment of the rate of decline of lung function with Tiotropium in patients with COPD
• Tiotropium
• 155 patients included
• Argentina

 

OBSERVATIONAL STUDY

• A Study of Clinical Observations and Outcomes Following a Pharmacological Stress SPECT Myocardial Perfusion Imaging Procedure . 
• 605 patients included
• Argentina, Chile and Brazil

 

PROFESS

• Agrenox vs Clopidrogrel with and without Micardis for recurrent stroke prevention
• Agrenox / Clopidogrel
• 534 patients included
• Lancet Neurol. 2008 Oct;7(10):875-84. Epub 2008 Aug 29
• Argentina

 

AMADEO

• Micardis vs losartan in diabetic patients
• Micardis / Losartan
• 62 patients included
• Kidney Int. 2008; 74(3):364-369
• Argentina

 

BEAUTIFUL

• Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction.
• Ivabradine
• 613 patients included
• The Lancet. Vol 372, No 9641, 807-816
• Argentina

 

RELY

• Randomized Evaluation of Long-term anticoagulant therapy comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
• dabigatran etexilate
• 527 patients included
• Circulation. 2011 May 31;123(21):2363-72. Epub 2011 May 16.
• Argentina

 

SOLSTICE

• A randomized, double-blind, double-dummy, parallel group trial comparing 12 weeks treatment with tiotropium inhalation capsules 18 mcg via the HandiHaler® once daily to Combivent® Inhalation Aerosol CFC MDI 2 actuations q.i.d. in COPD patients currently prescribed Combivent® Inhalation Aerosol CFC MDI.
• Tiotropium-Combivent
• 124 patients included
• Argentina

 

OASIS-VII

• Comparison of a high loading dose regimen of clopidogrel versus standard dose on cardiovascular events
• Clopidogrel
• 2223 patients included
• Lancet. 2010 Oct 9;376(9748):1233-43.
• Argentina, Mexico, Chile and Brazil

 

1012.56

• Comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12-week, double- blind, safety and efficacy study in adults with chronic obstructive pulmonary disease
• ipratropium bromide/salbutamol delivered by Respimat inhaler vs MDI inhaler
• 66 patients included
• Argentina

 

TIMACS

• Comparison early versus delayed invasive strategies in patients with non-ST segment elevation coronary acute syndromes
• No drugs tested
• 61 patients included
• Argentina

 

SHIFT

• Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction
• Ivabradine
• 246 patients included
• The Lancet – Published online August 29, 2010 DOI:10.1016 / S0140-6736(10)61198-1
• Brazil

 

EXACTT A

• randomized, double blind placebo controlled 2-year trial to examine the changes to exercise endurance in COPD patients treated with Tiotropium
• Tiotropium
• 31 patients included
• Argentina

 

EXPLORE Xa

• Phase 2, randomized, parallel group, dose finding, multicenter, multinational study of the efficacy, safety and tolerability of up to three blinded doses of an oral factor Xa inhibitor (study drug) compared with open label dose adjusted warfarin in patients with non-valvular atrial fibrillation
• Betrixaban
• Argentina

 

AVD

• Evaluate the Effect of AVANDIA™ on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus
• Rosiglitazone
• 40 patients included
• Argentina

 

FFR

• A randomized, double blind, placebo controlled, parallel groups, multicentric study to evaluate the effects of a 1-year cycle of 110 mcg QD of Fluticasona Fluorate in pediatric pre-puber subjects with alergic rinnitis
• Fluticasona Fuorate
• 86 patients included
• Argentina

 

VBK12

• Safety of a Second Dose of Biken’s Varicella Vaccine Administered at 4 to   6 Years of Age in Healthy Children in Argentina
• Live Attenuated Varicella Virus Vaccine Biken (Varicela Biken)
• 122 patients included
• Argentina

 

RECREATE

• An International Multicentre Randomized Controlled Trial of Intensive Insulin Therapy Targeting Normoglycemia In Acute MI Infarction: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) pilot study
• Insulin
• 1 patient included
• Argentina

 

OASIS VIII

• Fondaparinux trial with UFH during revascularization in ACS
• Fondaparinux / UFH
• 76 patients included
• Am Heart J. 2010 Dec;160(6):1029-34, 1034.e1.
• Argentina

 

SMOOTH

• A prospective, randomized, open-label, blinded end-point, forced-titration trial to compare MICARDIS PLUS/MICARDIS HCT to DIOVAN HCT, for the control of mild-to-moderate hypertension in overweight and obese patients with type-2 diabetes mellitus using ambulatory blood pressure monitoring.
• Micardis/Diovan
• 33 patients included
• Cardiovasc Diabetol. 2007; 6: 28.
• Argentina

 

ORIGIN

• Outcome reduction with initial glargine intervention
• Glargine Insuline/Omega 3 fatty acids
• 2222 patients included
• N Engl J Med 2012; 367:319-328
• Argentina

 

TOPCAT

• Treatment of preserved cardiac function heart failure with an aldosterone antagonist
• Spironolactone
• 123 patients included
• N Engl J Med 2014; 370:1383-1392; April 10, 2014
• Argentina

 

HOPE-3

• Study of Lipid Modification and Blood Pressure Reduction in People at Average Risk Candesartan/HCT
• Rosuvastatin
• 1459 patients included
• N Engl J Med. 2016 May 26;374(21):2032-43
• Argentina

 

INTERSTROKE

• Importance of conventional and emerging risk factors for stroke
• 296 patients included
• Lancet. 2016 Aug 20;388(10046):761-75
• Argentina

 

CONRAD

• Sperm Suppression and Contraceptive Protection Provided by Norethisterone Enantate (NET-EN) Combined with Testosterone Undecanoate (TU) in Healthy Men
• Norethisterone enantate (NET-EN)
• 63 patients included
• Chile

 

SIGNIFY

• Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure
• Ivabradine
• 983 patients included
• N Engl J Med. 2014 Sep 18;371(12):1091-9.
• Argentina, Uruguay

 

ASPIRE

• Aspirin to prevent recurrent venous thromboembolism
• Aspirin
• N Engl J Med 2012; 367:1979-198
• Argentina

 

ELIXA

• A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetic patients after an Acute Coronary Syndrome event
• Lixisenatide
• 399 patients included
• N Engl J Med. 2015 Dec 3;373(23):2247-57.
• Argentina

 

APOLLO

• Effects of Aliskiren in the prevention of major cardiovascular events in eldery people
• Aliskiren, HCTZ Amlodipine
• 516 patients included
• Eur Heart J. 2014 Jul;35(26): 1743-51.
• Argentina

 

ORIGINALE

• Long-Term Follow–up of the ORIGIN Participants
• Diabetes Care. 2016 May;39(5):709-16
• Argentina

 

INTER CHF

• An international registry to study the current causes, treatment, barriers to care, and outcome of heart failure in Africa, Asia and South America
• 308 participants included
• Am Heart J. 2015 Oct;170(4):627-634
• Argentina

 

ISIS 404173-CS2

• A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 404173 Administered Once Weekly to Obese Patients With Type 2 Diabetes Mellitus Being Treated With Metformin or Metformin Plus Sulfonylurea
• ISIS 404173
• 7 patients included
• Argentina

 

REGISTRY

• A registry of high-risk patients with coronary or peripheral artery disease
• Argentina

 

REWIND

• The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes
• Dulaglutide
• 1395 patients included
• Argentina

 

ISCHEMIA

• International study of comparative health effectiveness with medical and invasive approaches
• 24 patients included
• Argentina

 

MANAGE

• A large, international, randomized, placebo-controlled trial to assess the impact of dabigatran (a direct thrombin inhibitor) and omeprazole (a proton-pump inhibitor) in patients suffering myocardial injury after noncardiac surgery
• Dabigatran/Omeprazole
• 27 patients included
• Argentina

 

COMPASS

• A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease
• Rivaroxaban/Aspirin/Pantoprazole
• 3433 patients included
• Argentina, Chile

 

Hypertension Program Program for detection and management of arterial hypertension “Rosario controls its blood Pressure”

• 1078 patients included 
• Argentina

 

COLCOT

• Colchicine Cardiovascular Outcomes Trial
• Colchicine
• 841 patients included
• Argentina

 

DALGENE

• Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE)
• Dalcetrapib
• 212 patients included 
• Argentina, Chile

 

GALACTIC

• A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction
• Omecamtiv Mecarbil
• 71 patients included
• Argentina, Chile

 

G-CHF

• A global registry to study the demographics, socioeconomic and clinical factors, etiologies, pathophysiology, management, barriers to care, and outcomes of heart failure patients
• 472 patients included 
• Argentina

 

LTOLE

• Long-term open-label extension -COMPASS
• Rivaroxaban
• 753 patients included
• Argentina, Chile

 

Strong

• Dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.
• Guideline-directed medical therapies.
• 53 patients included
• The Lancet, December 03, 2022, Volume 400, Issue 10367P1938-1952.
• Colombia y Argentina

 

ASPEN

• evaluates the hypothesis that rNAPc2 (AB201) shortens time to recovery compared to heparin in hospitalized patients with COVID-19 and elevated D-dimer levels.
• rNAPc2 and Heparin,
• 4 patients.
• American Heart Journal, April 2022, Vol 246, pages 136-143
• Argentina

 

Colcovid

• test the effects of colchicine on moderate/high-risk hospitalized COVID-19 patients with the aim of reducing mortality and/or new requirement for mechanical ventilation.
• Colchicine
• 1279 patients
• Argentina

 

ACT

• ACT is a randomized clinical trial to assess therapies to reduce the clinical progression of COVID-19.
• Colchicine, Interferon Beta, Aspirin, Rivaroxaban
• 1436 patients included
• CJC Open, 2022 Mar 1;4(6):568–576. doi: 10.1016/j.cjco.2022.02.010
• Argentina

 

PREPARE-IT

• Prevention and Treatment of COVID-19 with EPA in at-Risk Subjects – Intervention Trial.
• EPA
• 2042 patients included
• Argentina

 

Seismic B y Seismic C

• Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC B) and Cardiogenic Shock (SEISMiC C).
• Istaroxime
• 8 patients (6 on SEISMiC B and 2 on SEISMiC C)
• J Heart Lung Transplant. 2025 May 30:S1053-2498(25)01977-1.doi: 10.1016/j.healun.2025.05.013.
• Argentina

 

ASPIRE-AF

• Study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient perioperative atrial fibrillation after noncardiac surgery and additional stroke risk factors.
• NOACs
• 4 patients included
• Argentina
• Ongoing

 

PURE

• Prospective Urban and Rural Epidemiological Study
• Observational study
• 7535 patients included
• Argentina
• Ongoing

 

COLT-HF

• Colchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease.
• Colchicine, placebo and Thiame Mononitrate
• Argentina
• Ongoing

 

LEADER-PAD

• Low dose Colchicine in patients with peripheral Artery Disease to address residual vascular risk
• Colchicine
• Argentina
• Ongoing